Literature DB >> 17132815

SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.

Taline V Khroyan1, Nurulain T Zaveri, Willma E Polgar, Juan Orduna, Cris Olsen, Faming Jiang, Lawrence Toll.   

Abstract

We identified a novel nociceptin/orphanin FQ (NOP)/mu-opioid receptor agonist, SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], with high binding affinity and partial agonist activity at both receptors. It was hypothesized that SR 16435 would produce antinociception and yet, unlike morphine, would have diminished rewarding properties and tolerance development. Antinociception was assessed in mice using the tail-flick assay, whereas behavioral and rewarding effects were assessed using the place conditioning (PC) paradigm. PC was established by pairing drug injections with a distinct compartment. Behavioral effects were measured after acute and repeated drug administration, and the test for PC was carried out 24 h after four drug- and vehicle-pairing sessions. SR 16435 produced an increase in tail-flick latency, but SR 16435-induced antinociception was lower than that observed with morphine. Given that naloxone blocked SR 16435-induced antinociception, it is highly likely that this effect was mediated by mu-opioid receptors. Compared with morphine, chronic SR 16435 treatment resulted in reduced development of tolerance to its antinociceptive effects. SR 16435-induced conditioned place preference (CPP) was evident, an effect that was probably mediated via mu-opioid receptors, as it was reversed by coadministration of naloxone. NOP agonist activity was also present, given that SR 16435 decreased global activity, and this effect was partially reversed with the selective NOP antagonist, SR 16430 [1-(cyclooctylmethyl)-4-(3-(trifluoromethyl)phenyl)piperidin-4-ol]. Naloxone, however, also reversed the SR 16435-induced decrease in activity, indicating that both opioid and NOP receptors mediate this behavior. In summary, the mixed NOP/mu-opioid partial agonist SR 16435 exhibited both NOP and mu-opioid receptor-mediated behaviors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132815     DOI: 10.1124/jpet.106.111997

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

2.  Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.

Authors:  Derek Vang; Jinny A Paul; Julia Nguyen; Huy Tran; Lucile Vincent; Dennis Yasuda; Nurulain T Zaveri; Kalpna Gupta
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

3.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

4.  Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.

Authors:  V Blair Journigan; Willma E Polgar; Taline V Khroyan; Nurulain T Zaveri
Journal:  Bioorg Med Chem       Date:  2014-03-05       Impact factor: 3.641

5.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

Review 6.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

7.  Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.

Authors:  Michael E Meyer; Arpit Doshi; Dennis Yasuda; Nurulain T Zaveri
Journal:  AAPS J       Date:  2021-05-11       Impact factor: 4.009

8.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

9.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

10.  Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.

Authors:  Taline V Khroyan; Willma E Polgar; Juan Orduna; Faming Jiang; Cris Olsen; Lawrence Toll; Nurulain T Zaveri
Journal:  Eur J Pharmacol       Date:  2009-03-12       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.